Enzyme News and Research

RSS

Novel study deepens understanding of how chromosome replication works

A novel study from the Swedish medical university Karolinska Institutet has deepened the understanding of how chromosome replication, one of life's most fundamental processes, works.

3 Mar 2011

Turmeric may be 'the right spice' to fight colon cancer

Turmeric, a bright yellow spice from south Asia belonging to the ginger family, is the main ingredient in curries - and ancient wisdom suggests that it's also good for your health. Taking this wisdom to the laboratory, Tel Aviv University researchers have discovered that turmeric's active ingredient called curcumin amplifies the therapeutic activity of highly toxic anti-inflammatory drugs used to fight colon cancer when used at high doses.

3 Mar 2011

Scientists provide new insight into mechanisms controlling programmed cell death pathways

Work led by St. Jude Children's Research Hospital investigators provides fresh insight into mechanisms controlling programmed cell death pathways and offers new targets in the fight against cancer and virus-infected cells

3 Mar 2011

Promising new way to lower cholesterol production

A promising new way to inhibit cholesterol production in the body has been discovered, one that may yield treatments as effective as existing medications but with fewer side-effects.

3 Mar 2011

BigThink.com launches breakthroughs: Discussion highlighting cutting-edge cancer research

Everyone knows someone that has been touched by cancer. Over one and a half million Americans will be diagnosed with some form of cancer in 2011, and more than 560,000 will die from the disease, accounting for 1 out of every 5 deaths.

2 Mar 2011

Glycogen study findings shed light on possible route to treat Lafora disease

Indiana University scientists have solved a perplexing mystery regarding one of the body's main energy storage molecules, in the process shedding light on a possible route to treatment of a rare but deadly disease in teenagers.

2 Mar 2011

Experimental drug may help preserve neurological function in survivors of sudden cardiac arrest

An experimental drug that targets a brain system that controls inflammation might help preserve neurological function in people who survive sudden cardiac arrest, new research suggests.

2 Mar 2011

NCI sponsors multi-center phase 2 study of entinostat-anastrozole combination in triple negative breast cancer

Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, announced the National Cancer Institute (NCI) will sponsor a multi-center phase 2 study of Syndax's lead product entinostat, a novel inhibitor of histone deacetylases (HDAC), and anastrozole, an aromatase inhibitor, in postmenopausal women with operable triple negative breast cancer to evaluate biomarkers and surrogates for response.

2 Mar 2011

New study: Enzyme that metabolizes vitamin D can predict lung cancer survival

Recent research suggests vitamin D may be able to stop or prevent cancer. Now, a new study finds an enzyme that plays a role in metabolizing vitamin D can predict lung cancer survival.

1 Mar 2011

European Commission approves BMY's BARACLUDE(r) to treat CHB in adult patients with liver disease

Bristol-Myers Squibb announced today that BARACLUDE(R) has been approved by the European Commission on February 28th 2011 to treat chronic hepatitis B in adult patients with evidence of decompensated liver disease.

1 Mar 2011

FDA approves roflumilast to treat COPD

The U.S. Food and Drug Administration approved roflumilast, a pill taken daily to decrease the frequency of flare-ups or worsening of symptoms from severe chronic obstructive pulmonary disease.

1 Mar 2011

New drug approved for COPD by the FDA

The U.S. FDA has approved a new treatment for people with worsening symptoms of severe chronic obstructive pulmonary disease (COPD). COPD affects smokers and the elderly and leads to severe difficulty in breathing, chronic cough and excessive mucus production. An exacerbation can last up to several weeks and result in a decline in lung function and increased risk of death, and it may be associated with severe anxiety, the FDA says.

1 Mar 2011

Gut bacteria could exert control over metabolic functions of other organs

Bacteria in the human gut may not just be helping digest food but also could be exerting some level of control over the metabolic functions of other organs, like the liver, according to research published this week in the online journal mBio-. These findings offer new understanding of the symbiotic relationship between humans and their gut microbes and how changes to the microbiota can impact overall health.

1 Mar 2011

New personalized therapy fools cancer cells into killing themselves

A Wayne State University School of Medicine physician-researcher has developed a personalized therapy to treat a wide range of cancers. The treatment is based on a naturally occurring human enzyme that has been genetically modified to fool cancer cells into killing themselves.

1 Mar 2011

Dermatan sulfate holds potential as an additional biomarker for Sanfilippo disease

Sanfilippo disease is a rare disorder caused by the failure of enzymes to break down specific kinds of complex carbohydrates, resulting in their accumulation in cells and often severe physical and neurological problems - and sometimes early death.

1 Mar 2011

TCD announces first patient treated in its TCD-717 Phase I trial

Traslational Cancer Drugs Pharma, S.L. (“TCD”) announced today that the first patient was treated on Friday the 18th of February with TCD-717 in a Phase I study performed in patients with advanced solid tumors. TCD-717 is a first-in-class, small molecule that precisely inhibits Choline Kinase Alpha, an enzyme heavily involved in the carcinogenic process. A total of 30 patients are planned to be treated in the trial, which will be conducted in accordance with FDA approval, in two leading medical centers in the U.S. The Principal Investigators are Dr. Julie Brahmer at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital in Baltimore; and Dr. Patricia LoRusso at the Barbara Ann Karmanos Cancer Institute in Detroit.

28 Feb 2011

Synageva supports Fourth International Rare Disease Day

Synageva BioPharma Corp., a privately held biopharmaceutical company that is developing therapeutic products for rare disorders, announced today that the company is supporting the Fourth International Rare Disease Day observance on February 28, 2011.

28 Feb 2011

EcoNugenics introduces CIRCUTOL Cardiovascular Health Support

Just in time for Heart Health Month, EcoNugenics introduces CIRCUTOL Cardiovascular Health Support. EcoNugenics has once again demonstrated excellence in being at the forefront of the latest developments in natural alternative health solutions.

28 Feb 2011

Evolutionary changes may have influenced metabolism and increased risk of diabetes

Researchers at the University of California, San Diego School of Medicine and Rady Children's Hospital-San Diego say an evolutionary gene mutation that occurred in human millions of years ago and our subsequent inability to produce a specific kind of sugar molecule appears to make people more vulnerable to developing type 2 diabetes, especially if they're overweight.

25 Feb 2011

Enobia completes patient enrollment in ENB-0040 Phase II study for HPP

Enobia Pharma Inc., today announced that it has successfully completed enrollment in its Phase II study of ENB-0040, a bone targeted enzyme replacement therapy being investigated in adolescents and adults with hypophosphatasia, a serious, rare metabolic bone disorder.

25 Feb 2011